(Q40993578)

25 September 2017

title

Screening for viral hepatitis prior to rituximab chemotherapy (English)

1 reference

25 September 2017

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Leann Norris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

A N Leonard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S K Siddiqui

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M N Wallam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

C L Bennett

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

18 September 2015

1 reference

25 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

27-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26382277%20AND%20SRC:MED&resulttype=core&format=json

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Epidemiology of hepatitis C virus infection in American veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Association between hepatitis C infection and other infectious diseases: a case for targeted screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Low rates of hepatitis B virus screening at the onset of chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Low level of hepatitis B virus screening among patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0

The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2502-0